The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

By Yadarisa Shabong Jan 20 (Reuters) - Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV ...

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...

Pfizer (PFE) posted Q3 revenue of $16.65B down 5.9% as COVID products declined sharply. Paxlovid dropped 55% and Comirnaty fell 20%. Teva (TEVA) delivered its 11th consecutive quarter of growth with ...

On July 30, 2025, the U.S. District Court for the District of Delaware entered a Final Judgment in the dispute between Alnylam Pharmaceuticals, Inc. (“Alnylam”) and Pfizer, Inc. (“Pfizer”)—concluding ...

Orient Pharma was hit with a patent infringement lawsuit on June 16 in Delaware District Court over its attempt to market generic versions of Pfizer's Xeljanz XR treatment for autoimmune conditions.

Pfizer is one of the world's largest and oldest drug companies. Thanks to its Covid vaccine, shares rose dramatically during the pandemic. Now that the stock has sharply corrected, long-term investors ...

Pfizer is one of the world's largest pharmaceutical companies. It has a few material patent expirations on the horizon. It's doing what it has to do to deal with that headwind and others. Pfizer is ...